Literature DB >> 27864876

Kinase gene fusions in defined subsets of melanoma.

Jacqueline Turner1, Kasey Couts1, Jamie Sheren1, Siriwimon Saichaemchan1, Witthawat Ariyawutyakorn1, Izabela Avolio1, Ethan Cabral1, Magdelena Glogowska1, Carol Amato1, Steven Robinson1, Jennifer Hintzsche1, Allison Applegate1, Eric Seelenfreund1, Rita Gonzalez1, Keith Wells1, Stacey Bagby1, John Tentler1, Aik-Choon Tan1, Joshua Wisell2, Marileila Varella-Garcia1, William Robinson1.   

Abstract

Genomic rearrangements resulting in activating kinase fusions have been increasingly described in a number of cancers including malignant melanoma, but their frequency in specific melanoma subtypes has not been reported. We used break-apart fluorescence in situ hybridization (FISH) to identify genomic rearrangements in tissues from 59 patients with various types of malignant melanoma including acral lentiginous, mucosal, superficial spreading, and nodular. We identified four genomic rearrangements involving the genes BRAF, RET, and ROS1. Of these, three were confirmed by Immunohistochemistry (IHC) or sequencing and one was found to be an ARMC10-BRAF fusion that has not been previously reported in melanoma. These fusions occurred in different subtypes of melanoma but all in tumors lacking known driver mutations. Our data suggest gene fusions are more common than previously thought and should be further explored particularly in melanomas lacking known driver mutations.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  acral; kinase; melanoma; pan-negative; rearrangement

Mesh:

Substances:

Year:  2017        PMID: 27864876      PMCID: PMC5349025          DOI: 10.1111/pcmr.12560

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  48 in total

1.  Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.

Authors:  Alexander M Menzies; Lauren E Haydu; Lydia Visintin; Matteo S Carlino; Julie R Howle; John F Thompson; Richard F Kefford; Richard A Scolyer; Georgina V Long
Journal:  Clin Cancer Res       Date:  2012-04-24       Impact factor: 12.531

2.  Anatomic site, sun exposure, and risk of cutaneous melanoma.

Authors:  David C Whiteman; Mark Stickley; Peter Watt; Maria Celia Hughes; Marcia B Davis; Adèle C Green
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

3.  Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.

Authors:  Alexander M Menzies; Iwei Yeh; Thomas Botton; Boris C Bastian; Richard A Scolyer; Georgina V Long
Journal:  Pigment Cell Melanoma Res       Date:  2015-07-03       Impact factor: 4.693

4.  Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.

Authors:  Porcia T Bradford; Alisa M Goldstein; Mary L McMaster; Margaret A Tucker
Journal:  Arch Dermatol       Date:  2009-04

5.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

6.  High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform.

Authors:  Maryou B K Lambros; Paul M Wilkerson; Rachael Natrajan; Neill Patani; Vidya Pawar; Radost Vatcheva; Marthe Mansour; Mirja Laschet; Beatrice Oelze; Nicholas Orr; Susanne Muller; Jorge S Reis-Filho
Journal:  Lab Invest       Date:  2011-08-01       Impact factor: 5.662

7.  The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.

Authors:  Jeffrey S Ross; Kai Wang; Juliann Chmielecki; Laurie Gay; Adrienne Johnson; Jacob Chudnovsky; Roman Yelensky; Doron Lipson; Siraj M Ali; Julia A Elvin; Jo-Anne Vergilio; Steven Roels; Vincent A Miller; Brooke N Nakamura; Adam Gray; Michael K Wong; Philip J Stephens
Journal:  Int J Cancer       Date:  2015-09-08       Impact factor: 7.396

8.  Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.

Authors:  Michael Krauthammer; Yong Kong; Antonella Bacchiocchi; Perry Evans; Natapol Pornputtapong; Cen Wu; Jamie P. McCusker; Shuangge Ma; Elaine Cheng; Robert Straub; Merdan Serin; Marcus Bosenberg; Stephan Ariyan; Deepak Narayan; Mario Sznol; Harriet M Kluger; Shrikant Mane; Joseph Schlessinger; Richard P Lifton; Ruth Halaban
Journal:  Nat Genet       Date:  2015-07-27       Impact factor: 41.307

9.  Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease.

Authors:  Luca Toschi; Giovanna Finocchiaro; Teresa T Nguyen; Margaret C Skokan; Laura Giordano; Letizia Gianoncelli; Matteo Perrino; Licia Siracusano; Luca Di Tommaso; Maurizio Infante; Marco Alloisio; Massimo Roncalli; Marta Scorsetti; Pasi A Jänne; Armando Santoro; Marileila Varella-Garcia
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

10.  Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

Authors:  A Vaishnavi; M Capelletti; P A Jänne; R C Doebele; A T Le; S Kako; M Butaney; D Ercan; S Mahale; K D Davies; D L Aisner; A B Pilling; E M Berge; J Kim; H Sasaki; S Park; G Kryukov; L A Garraway; Peter S Hammerman; J Haas; S W Andrews; D Lipson; P J Stephens; V A Miller; M Varella-Garcia
Journal:  Nat Med       Date:  2013-10-27       Impact factor: 53.440

View more
  12 in total

Review 1.  Unclassified sclerosing malignant melanomas with AKAP9-BRAF gene fusion: a report of two cases and review of BRAF fusions in melanocytic tumors.

Authors:  Emilie Perron; Daniel Pissaloux; Angela Neub; Daniel Hohl; Marie Dominique Tartar; Laurent Mortier; Laurent Alberti; Arnaud de la Fouchardiere
Journal:  Virchows Arch       Date:  2018-02-21       Impact factor: 4.064

2.  Targeted Genomic Profiling of Acral Melanoma.

Authors:  Iwei Yeh; Eric Jorgenson; Ling Shen; Mengshu Xu; Jeffrey P North; A Hunter Shain; David Reuss; Hong Wu; William A Robinson; Adam Olshen; Andreas von Deimling; Pui-Yan Kwok; Boris C Bastian; Maryam M Asgari
Journal:  J Natl Cancer Inst       Date:  2019-10-01       Impact factor: 13.506

3.  ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms.

Authors:  Kasey L Couts; Judson Bemis; Jacqueline A Turner; Stacey M Bagby; Danielle Murphy; Jason Christiansen; Jennifer D Hintzsche; Anh Le; Todd M Pitts; Keith Wells; Allison Applegate; Carol Amato; Pratik Multani; Edna Chow-Maneval; John J Tentler; Yiqun G Shellman; Matthew J Rioth; Aik-Choon Tan; Rene Gonzalez; Theresa Medina; Robert C Doebele; William A Robinson
Journal:  Mol Cancer Ther       Date:  2017-10-20       Impact factor: 6.261

Review 4.  The mutational landscape of mucosal melanoma.

Authors:  Kelsey W Nassar; Aik Choon Tan
Journal:  Semin Cancer Biol       Date:  2019-10-23       Impact factor: 15.707

Review 5.  Targeting Oncogenic BRAF: Past, Present, and Future.

Authors:  Aubhishek Zaman; Wei Wu; Trever G Bivona
Journal:  Cancers (Basel)       Date:  2019-08-16       Impact factor: 6.639

6.  BRAF fusions identified in melanomas have variable treatment responses and phenotypes.

Authors:  Jacqueline A Turner; Judson G T Bemis; Stacey M Bagby; Anna Capasso; Betelehem W Yacob; Tugs-Saikhan Chimed; Robert Van Gulick; Hannah Lee; Richard Tobin; John J Tentler; Todd Pitts; Martin McCarter; William A Robinson; Kasey L Couts
Journal:  Oncogene       Date:  2018-09-25       Impact factor: 8.756

7.  The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).

Authors:  Dara L Aisner; Lynette M Sholl; Lynne D Berry; Michael R Rossi; Heidi Chen; Junya Fujimoto; Andre L Moreira; Suresh S Ramalingam; Liza C Villaruz; Gregory A Otterson; Eric Haura; Katerina Politi; Bonnie Glisson; Jeremy Cetnar; Edward B Garon; Joan Schiller; Saiama N Waqar; Lecia V Sequist; Julie Brahmer; Yu Shyr; Kelly Kugler; Ignacio I Wistuba; Bruce E Johnson; John D Minna; Mark G Kris; Paul A Bunn; David J Kwiatkowski
Journal:  Clin Cancer Res       Date:  2017-12-07       Impact factor: 13.801

8.  Morpho-Molecular Assessment Indicates New Prognostic Aspects and Personalized Therapeutic Options in Sinonasal Melanoma.

Authors:  Sandra N Freiberger; Grégoire B Morand; Patrick Turko; Ulrich Wager; Reinhard Dummer; Martin Hüllner; David Holzmann; Niels J Rupp; Mitchell P Levesque
Journal:  Cancers (Basel)       Date:  2019-09-07       Impact factor: 6.639

Review 9.  Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours.

Authors:  Emily L Paton; Jacqueline A Turner; Isabel R Schlaepfer
Journal:  J Oncol       Date:  2020-01-03       Impact factor: 4.375

10.  Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma.

Authors:  Dinesh Pradhan; George Jour; Denái Milton; Varshini Vasudevaraja; Michael T Tetzlaff; Priyadharsini Nagarajan; Jonathan L Curry; Doina Ivan; Lihong Long; Yingwen Ding; Ravesanker Ezhilarasan; Erik P Sulman; Adi Diab; Wen-Jen Hwu; Victor G Prieto; Carlos Antonio Torres-Cabala; Phyu P Aung
Journal:  Cancers (Basel)       Date:  2019-12-16       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.